Skip to content

Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction

Effects of Nicorandil on Cardiac Sympathetic Nerve Activity and Distribution in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04826497
Enrollment
80
Registered
2021-04-01
Start date
2021-04-30
Completion date
2022-02-28
Last updated
2021-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

nicorandil, primary percutaneous coronary intervention, acute ST segment elevation myocardial infarction, cardiac sympathetic nerve

Brief summary

The investigators evaluate the effects of intracoronary and intravenous administration of nicorandil on cardiac sympathetic nerve activity and distribution in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Detailed description

Reperfusion injury might occur in patients with acute ST segment elevation myocardial infarction undergoing the primary percutaneous coronary intervention(P-PCI),characterized by myocardial stunning, reperfusion-induced arrhythmia, microvascular dysfunction and injury of cardiac sympathetic nerve, etc. Nicorandil is an antianginal agent with a dual mechanism of action: nitrate and K+ATP channel opener. The nitrate action causes vasodilation of systemic veins and epicardial coronary arteries, while the adenosine triphosphate (ATP)-sensitive potassium channel opener action causes vasodilation of peripheral and coronary resistance arterioles. Nicorandil not only decreases preload and afterload but also increases coronary blood flow. The study will compare the effectiveness between nicorandil and placebo of preventing the reperfusion injury especially injury of cardiac sympathetic nerve in patients with acute ST segment elevation myocardial infarction undergoing the P-PCI.It is intended that before reperfusion injury ,nicorandil which was early used by intracoronary injection could prevent and release the microcirculatory spasm, release the coronary microvascular endothelial swelling,decrease embolism of atherosclerotic debris and thrombus formation,moreover,it could reduces the release of norepinephrine from sympathetic endings of the heart directly.So,it could decrease the phenomenon of no-reflow/slow reflow,reperfusion-induced arrhythmia and injury of cardiac sympathetic nerve.

Interventions

DRUGnicorandil

All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention

All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention

Sponsors

Xuzhou Central Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. acute ST-segment elevation myocardial infarction within 12 hours of symptom onset; 2. Age20-80,All genders 3. anterior myocardial infarction 4. The first myocardial infarction 5. The infarct-related artery(IRA) is totally occlusive 6. Blood pressure is higher than 90/60 millimeters of mercury(mmHg) 7. The time from myocardial infarction onset to reach the hospital is less than 12 hs

Exclusion criteria

1. kidney dysfunction (creatinine \>2 mg/dl), 2. History of previous liver disease, 3. Cardiogenic shock, 4. History of myocardial infarction (MI) 5. History of coronary artery bypass grafting 6. History of allergic response to drugs 7. Severe hypovolemia

Design outcomes

Primary

MeasureTime frameDescription
Comparison of the delayed heart/mediastinum count (H/M) ratio10 days after primary PCIThe delayed heart/mediastinum count (H/M) ratio was determined from 123I-meta-iodobenzylguanidine (MIBG) images

Secondary

MeasureTime frameDescription
The total defect score (TDS)10 days after primary PCIThe total defect score was determined from 123I-meta-iodobenzylguanidine (MIBG) images
Rate of slow re-flow/no-reflow phenomenon5 minutes after primary PCITIMI myocardial perfusion grade (TMPG) of the final coronary flow in the culprit artery
Rate fo complete ST-segment resolution2 hours after primary PCIST-segment resolution \>50 percent in ECG
Rate of unplanned hospitalization for heart failure6 months after primary PCIRate of unplanned hospitalization for heart failure
The washout rate (WR)10 days after primary PCIThe washout rate (WR) were determined from 123I-meta-iodobenzylguanidine (MIBG) images

Contacts

Primary Contactchunguang Feng, PhD
fcg999@163.com+8618936376559

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026